How is the Capizzi protocol administered in children (1‑14 years) with newly diagnosed acute lymphoblastic leukemia (ALL), particularly T‑cell lineage?

How to Administer the Capizzi Protocol in Pediatric ALL

The Capizzi interim maintenance regimen consists of escalating-dose intravenous methotrexate (starting at 100 mg/m² and increasing by 50 mg/m² every 10 days to a maximum of 300 mg/m²) without leucovorin rescue, combined with weekly vincristine 1.5 mg/m² (capped at 2 mg), intrathecal methotrexate, and PEG-asparaginase 2,500 U/m² every 2 weeks, administered during two 8-week interim maintenance phases following consolidation therapy. 1, 2

Regimen Components and Dosing

Methotrexate Administration

• Start with 100 mg/m² IV during week 1 of the 8-week interim maintenance cycle 1
• Escalate by 50 mg/m² every 10 days (weeks 2,4,6,8), reaching a maximum of 300 mg/m² by week 8 1, 2
• No leucovorin rescue is given—this is a critical distinguishing feature of the Capizzi approach 1, 2
• Administer as a 30-minute loading dose followed by the remaining 90% over 23.5 hours 2

Asparaginase Integration

• PEG-asparaginase 2,500 U/m² intramuscularly is given 24 hours after completion of each methotrexate infusion (every 2 weeks) 1, 2
• If PEG-asparaginase is unavailable, substitute with native E. coli asparaginase 10,000 U/m² administered on days 3,6,9,12,15, and 18 of each cycle 1

Vincristine Dosing

• 1.5 mg/m² IV once weekly throughout the entire 8-week cycle 1, 2
• Maximum single dose is capped at 2 mg regardless of body surface area 1

CNS Prophylaxis

• Intrathecal methotrexate on weeks 1 and 3 of each 8-week cycle 1, 2
• Age-adjusted dosing:
  • <1 year: 8 mg
  • 1–2 years: 10 mg
  • 2–3 years: 12 mg
  • ≥3 years: 15 mg 1

Treatment Sequence Within the Overall Protocol

The Capizzi regimen is embedded within a multi-phase treatment plan:

1. Induction (4 weeks): Four-drug regimen with corticosteroid, vincristine, anthracycline, and pegaspargase 3
2. Consolidation I (8–12 weeks post-induction) 1
3. Interim Maintenance #1 (8 weeks): First Capizzi cycle 1
4. Delayed Intensification #1 (4 weeks) 1
5. Interim Maintenance #2 (8 weeks): Second Capizzi cycle, identical to the first 1
6. Delayed Intensification #2 (4 weeks): Reserved for high-risk patients only 1
7. Long-term maintenance (total 2–2.5 years from diagnosis): Daily mercaptopurine 37.5–50 mg/m², weekly methotrexate 15–20 mg/m², monthly vincristine pulses, and dexamethasone 4–6 mg/m² for 5 days every 4 weeks 1, 3

Safety Monitoring and Toxicity Management

Pre-Treatment Requirements

• Obtain complete blood count with differential before each methotrexate dose; absolute neutrophil count must exceed 750 cells/µL to proceed 1
• Measure serum creatinine at 24 and 48 hours after each methotrexate infusion to detect nephrotoxicity 2

Supportive Care Measures

• Aggressive hydration at 125–150 mL/m²/hour beginning 12 hours before infusion and continuing for 24–36 hours afterward 2
• Urine alkalinization to pH >7.0 with sodium bicarbonate to reduce methotrexate precipitation in renal tubules 2
• Monitor for asparaginase-related toxicities: coagulopathy, thrombosis, hyperglycemia, pancreatitis, and hepatotoxicity 2

Common Toxicities

The Capizzi regimen has a combined toxicity incidence of approximately 28.7%, with febrile neutropenia, thrombocytopenia, and hepatotoxicity being most common 4. Importantly, mucositis is significantly less frequent with Capizzi (5.5% of cycles) compared to high-dose methotrexate (14.6% of cycles, P=0.002) 4. Male gender, lower baseline ANC, and lower BMI are associated with increased toxicity risk 4.

Evidence for Efficacy

Superior Outcomes in T-Cell ALL

In patients ≤30 years with T-cell ALL, the Capizzi regimen yields superior outcomes compared to high-dose methotrexate (5 g/m²). The 5-year disease-free survival is 91.5% with Capizzi versus 85.3% with high-dose methotrexate (P=0.005), and overall survival is 93.7% versus 89.4% (P=0.04) 5. This superiority is particularly evident in CNS relapse prevention: Capizzi resulted in only 6 CNS relapses among 32 total relapses, whereas high-dose methotrexate resulted in 23 CNS relapses among 59 total relapses 5.

No Difference in B-Cell ALL

For B-cell ALL, no significant survival difference exists between Capizzi and high-dose methotrexate approaches 5, 6. A recent study of 105 pediatric B-ALL patients found no significant difference in event-free or overall survival based on methotrexate regimen 6.

Excellent Overall Outcomes

The Children's Oncology Group AALL0434 trial, which utilized the Capizzi regimen, achieved 4-year event-free survival of 84.7% and overall survival of 89.0% in T-cell lymphoblastic lymphoma, with only 4 CNS relapses among 299 patients 7.

Dose Modifications and Contraindications

When to Reduce or Delay

• Renal impairment (creatinine clearance <60 mL/min): Reduce initial methotrexate dose by 50% and escalate more cautiously 2
• Significant hepatic dysfunction (transaminases >5× upper limit of normal): Requires dose reduction or regimen change 2
• Active infection: Postpone treatment until infection resolves 2
• Avoid inappropriate dose reductions when not clinically mandated, as this compromises therapeutic efficacy 2

Absolute Contraindications

• Pregnancy: Effective contraception must be maintained throughout treatment 2

Common Pitfalls and How to Avoid Them

1. Do not administer leucovorin rescue with Capizzi methotrexate—this fundamentally alters the regimen and eliminates its therapeutic advantage 1, 2

2. Ensure adequate CNS prophylaxis: Because Capizzi methotrexate achieves lower CSF concentrations than high-dose protocols, concurrent intrathecal methotrexate on weeks 1 and 3 is mandatory 2

3. Time asparaginase correctly: PEG-asparaginase must be given 24 hours after methotrexate completion to optimize synergy 2

4. Monitor for delayed methotrexate clearance: Even without leucovorin rescue, aggressive hydration and alkalinization are essential to prevent nephrotoxicity 2

5. Do not skip ANC checks: The requirement for ANC >750 cells/µL before each methotrexate dose is critical to prevent life-threatening infections 1